Overall survival and progression
24-month overall survival after RUX initiation was 81.2% for the entire cohort. Survival was dependent on IPSS scores, with survival in patients with low-, int-1–risk, int-2–risk, and high-risk scores being 79.6%, 91.1%, 80.7%, and 73.5%, respectively. Potential inconsistencies in these data are most likely caused by the large number of patients with missing IPSS data (270 out of 464 patients). Figure Overall survival analysis in JAKoMo patients (Kaplan–Meier estimator). (